These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8535326)

  • 1. Donor buffy coat infusions for a patient with myelodysplastic syndrome who relapsed following allogeneic bone marrow transplantation.
    Tsuzuki M; Maruyama F; Kojima H; Ezaki K; Hirano M
    Bone Marrow Transplant; 1995 Sep; 16(3):487-9. PubMed ID: 8535326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
    Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
    Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome.
    Shiobara S; Nakao S; Ueda M; Yamazaki H; Takahashi S; Asano S; Yabe H; Kato S; Imoto S; Maruta A; Yoshida T; Gondo H; Morishima Y; Kodera Y
    Bone Marrow Transplant; 2000 Oct; 26(7):769-74. PubMed ID: 11042659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation.
    Porter DL; Roth MS; Lee SJ; McGarigle C; Ferrara JL; Antin JH
    Bone Marrow Transplant; 1996 Nov; 18(5):975-80. PubMed ID: 8932854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activated allogeneic cell therapy (allo-ACT) for relapsed chronic myelogenous leukemia (CML) refractory to buffy coat transfusions post-allogeneic bone marrow transplantation.
    Kapelushnik J; Nagler A; Or R; Naparstek E; Ackerstein A; Samuel S; Morecki S; Nabet C; Slavin S
    Bone Marrow Transplant; 1996 Dec; 18(6):1153-6. PubMed ID: 8971387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapeutic effect of donor leukocyte transfusion in relapsing marrow transplants in Japan].
    Shiobara S; Takahasi S; Yabe H; Maruta I; Kodera Y
    Rinsho Ketsueki; 1997 Nov; 38(11):1162-9. PubMed ID: 9423332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular remission induced by fractionated dose-escalating donor leukocyte infusion without graft-versus-host disease in a patient with chronic myelogenous leukemia relapsed after allogeneic bone marrow transplantation.
    Inai K; Wano Y; Yamamoto S; Ikebata Y; Iwasaki H; Tsutani H; Naiki H; Ueda T
    Anticancer Res; 1999; 19(6C):5631-4. PubMed ID: 10697631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Achievement of complete cytogenetic remission after two very low-dose donor leucocyte infusions in a patient with extensive cGVHD relapsing in accelerated phase post allogeneic BMT for CML.
    Rahman SL; Mahendra P; Nacheva E; Sinclair P; Arno J; Marcus RE
    Bone Marrow Transplant; 1998 May; 21(9):955-6. PubMed ID: 9613792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors.
    Demuynck H; Verhoef GE; Zachee P; Emonds MP; van der Schueren E; van den Berghe H; Vandenberghe P; Casteels-Van Daele M; Boogaerts MA
    Bone Marrow Transplant; 1996 May; 17(5):745-51. PubMed ID: 8733692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Donor leucocyte transfusions for relapse in myelodyplastic syndrome after allogeneic bone marrow transplantation.
    Okumura H; Takamatsu H; Yoshida T
    Br J Haematol; 1996 May; 93(2):386-8. PubMed ID: 8639432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donor leukocyte infusions for treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation.
    Forés R; Díez-Martin JL; Briz M; Cabrera JR; Sanjuán I; Regidor C; Garcia-Talavera J; Fernandez MN
    Bone Marrow Transplant; 1996 Mar; 17(3):439-41. PubMed ID: 8704703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Graft-versus-host disease following bone marrow transplantation: clinical feature and diagnosis.
    Kikuta A; Suzuki H
    Fukushima J Med Sci; 1993 Dec; 39(2):95-9. PubMed ID: 7927140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
    Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
    Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Leukocyte transfusion as therapy of recurrent CML after allogenic bone marrow transplantation].
    Wiesneth M; Hertenstein B; Bunjes D; Novotny J; Stefanic M; Heinze B; Schreiner T; Kubanek B; Heimpel H; Arnold R
    Beitr Infusionsther Transfusionsmed; 1994; 32():276-80. PubMed ID: 9480108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced-intensity bone marrow transplantation from an alternative unrelated donor for myelodysplastic syndrome of first-donor origin.
    Komeno Y; Kanda Y; Kandabashi K; Kawazu M; Goyama S; Takeshita M; Nannya Y; Niino M; Nakamoto T; Kurokawa M; Tsujino S; Ogawa S; Aoki K; Chiba S; Motokura T; Hirai H
    Am J Hematol; 2003 Mar; 72(3):220-2. PubMed ID: 12605397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
    Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
    Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic bone marrow transplantation for myelodysplastic syndromes (MDS).
    Arnold R; Heimpel H
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():101-3. PubMed ID: 2697417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
    Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
    Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic peripheral blood progenitor cells for treatment of relapse after bone marrow transplantation.
    Glass B; Majolino I; Dreger P; Scimè R; Santoro A; Vasta S; Suttorp M; Haferlach T; Schmitz N
    Bone Marrow Transplant; 1997 Oct; 20(7):533-41. PubMed ID: 9337054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.